Drug Profile
Fenretinide oral - Laurent Pharmaceuticals/McGill University
Alternative Names: Fenretinide oral - Laurent Pharmaceuticals; LAU-7bLatest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Ortho-McNeil Pharmaceutical
- Developer Cystic Fibrosis Foundation Therapeutics; Laurent Pharmaceuticals; McGill University
- Class Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
- Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Cystic fibrosis
- No development reported Pseudomonal infections
Most Recent Events
- 20 Nov 2023 Phase-II/III clinical trials in COVID-2019 infections (Adjunctive treatment) in Canada (PO) (NCT05999435)
- 29 Aug 2023 Health Canada approves phase II/III ESSOR clinical trial for Fenretinide oral in COVID-2019 infections
- 24 Aug 2023 Laurent Pharmaceuticals plans a phase II/III ESSOR trial in post-acute COVID-19 syndrome (Adjunctive treatment) (PO, Capsule) in September 2023 (NCT05999435)